摘要
目的研究美罗华(Rituximab)联合FMD方案治疗复发、难治的B细胞淋巴瘤的临床疗效和不良反应.方法治疗第1天用美罗华375mg / m2,第2天开始用FMD方案(氟达拉滨50mg第1、2、3天、米西宁10mg/ m2第2天、地塞米松20mg第1～5天),共用4个周期.结果 10例完全缓解4例(40%),部分缓解5例(50%),有效率90%.3例(30%)发生Ⅲ～Ⅳ度中性粒细胞减少.结论美罗华联合FMD方案治疗复发、难治的B细胞淋巴瘤的临床疗效显著,没有增加不良反应.
Objective To evaluate the therapeutic effects and toxicity of combination of rituximab and FMD regimen in the treatment of relapsed-refractory non-Hodgkin＇s lymphoma in 10 patients. Methods This treatment consisted of rituximab 375mg/m^2 intravenously infusion on day 1, fludarabine 50mg on day 2-4, mitoxantrone 14mg/m^2 on day 2,dexamethasone 20mg on day 2-6. The patients received 4 infusion of the treatment, Results In 10 patients, 4（40%） complete response and 5（50%） partial response were observed. Thus, the overall response rate was 90%. The hematological toxicities were mainly neutropenia. 3 （30 %） experienced 3-4 grade neutropenia. Conclusion Our result suggests that rituximab in combination with chemotherapy in the treatment of relapsed-refractory B cell lymphoma is effective without additional toxicity.
出处
《重庆医学》
CAS
CSCD
2005年第9期1336-1337,共2页
Chongqing medicine
关键词
美罗华
B细胞性淋巴瘤
疗效
rituximab
B cell lymphoma
therapeutic effects
